Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Synthetic Peptide Non-Covalently Transports Cancer Drugs Across the Blood-Brain Barrier

By BiotechDaily International staff writers
Posted on 18 Jun 2014
Cancer researchers have used a novel synthetic peptide to transport chemotherapeutic compounds and other small molecules across the blood-brain barrier and into the brains of mice.

The transport peptide, K16ApoE, comprised sixteen lysine residues and 20 amino acids corresponding to the LDLR (low density lipoprotein receptor)-binding domain of apolipoprotein E (ApoE). Investigators at the Mayo Clinic (Rochester, MN, USA) had demonstrated previously that by mimicking a ligand-receptor system, K16ApoE could deliver three different proteins (beta-galactosidase, IgG, and IgM) in a non-covalent fashion across the blood-brain barrier. To their knowledge this was the first report demonstrating successful delivery of various proteins across the blood-brain barrier that did not involve chemically linking the proteins with a carrier entity.

In the current study, the investigators delivered chemotherapeutics and other agents into the brains of mice either by injecting the carrier peptide and the drugs separately or as a mixture via the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a small-molecule drug.

The investigators reported in the May 21, 2014, online edition of the journal PLOS ONE that seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the injection method, brain uptake was 34–50-fold greater for cisplatin and 54–92-fold greater for methotrexate with K16ApoE than without. Visually intense brain-uptake of the dyes Evans Blue, Light Green SF, and Crocein scarlet was also achieved. Direct intracranial injection of Evans Blue showed locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection resulted in the distribution of the dye throughout the brain.

"We know that some chemotherapeutic agents can kill brain tumor cells when they are outside the brain (as in a laboratory test). But because the agents cannot cross the blood-brain barrier, they are not able to kill brain tumor cells inside the brain. With the peptide carrier, these agents can now get into the brain and potentially kill the tumor cells," said senior author Dr. Robert Jenkins a neurology researcher at the Mayo Clinic.

Related Links:

Mayo Clinic



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.